Dicot Pharma AB publishes prospectus in connection with the upcoming rights issue

Uppsala, Sweden, August 14, 2024. The Board of Directors of Dicot Pharma AB today publishes an EU growth prospectus (the "Prospectus") in relation to the rights issue of units consisting of shares and warrants of series TO6 resolved by the Board of Directors on August 7, 2024 (the "Rights Issue"). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Dicot Pharma AB ("Dicot" or the "Company") is now carrying out a rights issue of units with the primary purpose of financing a clinical phase 2a study with the potency drug candidate LIB-01. The company also intends to start preparations for clinical phase 2b studies in parallel. Through the Rights Issue, Dicot, if fully subscribed, will initially receive approx. SEK 122.6 million before issue costs. The Rights Issue is secured to 65 percent through subscription commitments and guarantee commitments.

Upon full exercise of all warrants of series TO6, the Company may receive a maximum of approx. SEK 46 million before deduction of issue costs. The warrants will be admitted to trading on Spotlight Stock Market.

For complete information about the Rights Issue, please refer to the published Prospectus.

The prospectus

The prospectus has been prepared in connection with the upcoming Rights Issue and has today, August 14, 2024, been approved and registered by the Swedish Financial Supervisory Authority. The prospectus, containing complete terms and conditions, is available on the Company's and Aqurat Fondkommission AB's respective websites (www.dicotpharma.com, www.aqurat.se). The prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Information on how to subscribe and application forms will be available on the Company's and Aqurat Fondkommission AB's respective websites as of August 16, 2024. Furthermore, application forms will be available by contacting the issuing agent on telephone number +46 (8) 684 058 00.

Preliminary timetable for the Rights Issue

• August 16 – 27, 2024: Trading in unit rights
• August 16 – 30, 2024: Subscription period for the Rights Issue
• August 16, 2024 – until the Rights Issue has been registered with the Swedish Companies Registration Office: Trading in paid subscribed units (BTU)
• September 4, 2024: Estimated date for announcement of issue outcome

Advisor

Corpura Fondkommission AB is acting as Sole Coordinator and Joint Bookrunner together with Penser by Carnegie, Carnegie Investment Bank AB (publ) in connection with the Rights Issue and Advokatfirman Lindahl KB is acting as legal advisor. Aqurat Fondkommission AB acts as issuing agent.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,100 shareholders. For more information, please visit www.dicotpharma.com.

Important Information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Dicot. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Dicot takes place solely through the prospectus that the Company publish.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for securities in the United States. No shares, subscription rights or other securities issued by the Company ("Securities") have been registered, and no shares or other Securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, subscribed, exercised, pledged, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. The securities have not been approved or registered, and will not be approved or registered, by the U.S. Securities and Exchange Commission, any state securities regulator or any other authority in the United States. Nor has any such authority assessed or commented on the offering or the accuracy and reliability of the prospectus. To say the opposite is a criminal offense in the United States.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. In an EEA Member State, other than Sweden, this announcement is only intended for and is only directed at "qualified investors" in the respective Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document, and other materials relating to the securities referred to herein, are distributed and directed only to, and an investment or investment activity attributable to this document is only available to and will only be able to be exercised by "qualified investors" (in a sense in the UK version of Regulation (EU) 2017/1129 which is part of UK legislation by the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in dealings relating to investments and who fall within the definition of " investment professionals" in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Regulation"); (ii) "high net worth entities" etc. as referred to in Article 49(2)(a)-(d) of the Regulation; or (iii) such other persons to whom such investment or investment activity may lawfully be directed under the Regulations (all such persons are collectively referred to as "relevant persons"). An investment or an investment measure to which this notice relates is available in the United Kingdom only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons shall not take any action based on this document nor act or rely on it.

Forward-looking statements

This press release may contain forward-looking statements which reflect the Company's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.